Last updated 5 days ago

AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL

420 patients around the world

Available in Belgium, Brazil

AstraZeneca

420Patients around the world

This study is for people with

Non-Hodgkin Lymphoma

Large B-cell lymphoma

Requirements for the patient

To 130 Years

All Gender

Medical requirements

: Participants are either 80 years of age or older, OR 65 to 79 years of age or older and classified as unfit per sGA, and otherwise not considered candidates for full-dose R-CHOP per investigator assessment.
Histologically confirmed diagnosis of previously untreated LBCL as per WHO-HEM5 (excluding plasmablastic lymphoma) and follicular large cell lymphoma.
FDG-avid and measurable disease as per Lugano and Ann Arbor staging.
Stage I bulky (7.5 cm and greater) to Stage IV.
ECOG performance status 0 to 2.
Adequate bone marrow, liver, renal and cardiac function.

: As judged by the investigator, any evidence of diseases which make it undesirable for the participant to participate in the study, or that would jeopardise compliance with the protocol.
Diagnosis of post-transplant lymphoproliferative disease, plasmablastic lymphoma, Richter's transformation, prior history of or concurrent indolent lymphoma (including de novo transformed or composite lymphoma).
History of CNS involvement by their B-NHL or history of clinically relevant CNS medical condition.
Known history of hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS).
Active or uncontrolled infection.
Major cardiac abnormalities.
Prior anti-lymphoma therapy except for corticosteroids for symptom control.
Requires chronic immunosuppressive therapy for active autoimmune/inflammatory condition, with some exceptions.

StudySOUNDTRACK-D2

SponsorAstraZeneca

Study typeInterventional

Conditions

Large B-cell lymphoma

Requirements

To 130 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT07215585